ResMed shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform and announced a $180 price target.
Portfolio Pulse from Benzinga Newsdesk
ResMed shares declined following a downgrade by Wolfe Research from Peer Perform to Underperform, with a new price target of $180.
September 18, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed's stock was downgraded by Wolfe Research from Peer Perform to Underperform, with a price target set at $180, leading to a decline in share price.
The downgrade by Wolfe Research is a significant negative signal for investors, likely causing a short-term decline in ResMed's stock price. The new price target of $180 suggests a bearish outlook, contributing to the stock's downward movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100